Japanese drugmaker Eisai and US-based Biogen have been working together on advancing research in the space of Alzheimer’s for nearly a decade. Finally, the FDA, granted the fruits of that labor, Leqembi, its blessing for intravenous use. This marks the first approved treatment that can slow the progression of Alzheimer’s.

    • thorbot@lemmy.worldOP
      link
      fedilink
      English
      arrow-up
      9
      ·
      1 year ago

      Yeah, any news like this is heartening but I always take it with a large grain of salt. I’ve got family member affected by Alzheimer’s so it really hits home.